newsfilter
← Latest News
GlobeNewswire·

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027